Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Cerebral infarction? 16 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Cerebral infarction have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 0.2% of all adverse event reports for BRENTUXIMAB VEDOTIN.

16
Reports of Cerebral infarction with BRENTUXIMAB VEDOTIN
0.2%
of all BRENTUXIMAB VEDOTIN reports
6
Deaths
13
Hospitalizations

How Dangerous Is Cerebral infarction From BRENTUXIMAB VEDOTIN?

Of the 16 reports, 6 (37.5%) resulted in death, 13 (81.3%) required hospitalization, and 4 (25.0%) were considered life-threatening.

Is Cerebral infarction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BRENTUXIMAB VEDOTIN. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Neuropathy peripheral (695) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374)

What Other Drugs Cause Cerebral infarction?

RIVAROXABAN (1,367) APIXABAN (937) DABIGATRAN ETEXILATE (713) ASPIRIN (535) EDOXABAN (419) CLOPIDOGREL BISULFATE (315) PEMBROLIZUMAB (295) BEVACIZUMAB (269) METHOTREXATE (265) NIVOLUMAB (262)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Cerebral infarction Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Cerebral infarction Reports All Drugs Causing Cerebral infarction BRENTUXIMAB VEDOTIN Demographics